HOME >> BIOLOGY >> NEWS
A Jekyll-and-Hyde enzyme's role in Alzheimer's

Researchers have discovered how a brain enzyme important in the development and maintenance of learning and memory also plays a key role in the death of neurons in neurodegenerative disorder such as Alzheimer's disease (AD). They found that the enzyme's transformation from Jekyll to Hyde may be due to abnormal activation of the brain's mechanism to compensate for the damage from such diseases. This compensatory mechanism may also function in normal aging, they said.

In their article in the December 8, 2005, issue of Neuron, Li-Huei Tsai and colleagues said their findings in mice could offer a model to study how normal neural mechanisms can go awry to contribute to the brain degeneration of AD.

The researchers' studies concentrated on a key brain regulatory enzyme called Cdk5. Elevated levels of Cdk5 had been found in the brains of AD patients, as well as elevated levels of a regulatory protein called p25 that is known to hyperactivate Cdk5. Researchers had found that the hyperactivating p25 is produced when the normal regulatory protein for Cdk5, called p35, is snipped into the shorter p25 by another enzyme.

In their experiments, the researchers used mice in which they could switch on p25 at will in the brain's learning and memory center, the hippocampus. In these mice, they found that switching on p25 for only two weeks actually enhanced learning and memory compared to normal mice. The two-week p25 mice could learn more quickly to associate a tone or environment with a mild electrical shock and to find a platform submerged in a pool of murky water.

In contrast, found the researchers, mice in which p25 had been switched on for six weeks showed impaired learning and memory in these tasks. Physiological studies showed that these mice showed significant brain atrophy and loss of hippocampal neurons. The researchers also showed that the two-week pulse of p25 did not cause neurodegeneration and had long-lasting effects on enhancing memory.
'"/>

Contact: Heidi Hardman
hhardman@cell.com
617-397-2879
Cell Press
7-Dec-2005


Page: 1 2

Related biology news :

1. Nobel Laureate finds elegant explanation for DNA transcribing enzymes high fidelity
2. Gilbert Foundation and American Fed for Aging Research award grants on Alzheimers disease
3. Link identified between Alzheimers disease and glaucoma
4. UCF research links proteins, stem cells and potential Alzheimers treatment
5. Journal of Alzheimers Disease achieves significant impact factor
6. Alzheimers prevention role discovered for prions
7. Cloned pigs help scientists towards a breakthrough in Alzheimers
8. Alzheimers drug based on Purdue -- designed inhibitor begins clinical trials
9. Paving the way toward a vaccine against Alzheimers disease
10. Genetic fellow traveler discovered in Alzheimers
11. New clues to stroke role in Alzheimers

Post Your Comments:
*Name:
*Comment:
*Email:
TAG: Jekyll and Hyde enzyme role Alzheimer

(Date:12/10/2014)... N.C. , Dec. 9, 2014  Wake Forest Baptist ... education building for its School of Medicine. Funding for ... larger capital campaign that will be publicly launched next ... be located in the former 60 series R.J. Reynolds ... Innovation Quarter. Construction will begin immediately with plans to ...
(Date:12/5/2014)... MOUNTAIN VIEW, Calif. , Dec. 4, 2014 ... and safety has boosted investments in new testing ... products has also given rise to a range ... driven by the requirements of Generation Y, which ... digital technologies. As a result, product development strategies ...
(Date:12/3/2014)... , Dec. 2, 2014 As part ... readers, Inception Technologies is pleased to announce the release ... for customers to collect the workforce data that they ... that have been left by existing readers. Many such ... interface, connectivity and modern technology. Older models force users ...
Breaking Biology News(10 mins):Wake Forest Baptist to Build New Medical Education Facility In Wake Forest Innovation Quarter 2Wake Forest Baptist to Build New Medical Education Facility In Wake Forest Innovation Quarter 3Wake Forest Baptist to Build New Medical Education Facility In Wake Forest Innovation Quarter 4Emerging Technologies Enable Smarter Monitoring of Assets, Push Industrial Testing, Inspection and Monitoring Market 2Emerging Technologies Enable Smarter Monitoring of Assets, Push Industrial Testing, Inspection and Monitoring Market 3Emerging Technologies Enable Smarter Monitoring of Assets, Push Industrial Testing, Inspection and Monitoring Market 4Inception Technologies to Release New Biometric Reader 2
(Date:12/17/2014)... (PRWEB) December 17, 2014 Gene ... that it has entered into a technology access ... (ADM) to apply DNA2.0’s proprietary protein engineering technology, ... process. , “We are extremely excited that the ... platform. This proprietary bioengineering technology has now ...
(Date:12/17/2014)... SOUTH SAN FRANCISCO, Calif. , Dec. 17, ... positive results of a Phase 2 study evaluating ... for the treatment of patients with severe, chronic ... the current standard of care, including topical steroids ... endpoint was percent change in Visual Analog Scale ...
(Date:12/15/2014)...  GlassesOff Inc. (OTCBB: GLSO) announced today the appointment ... director of the Company,s Board of Directors. ... its CEO until its acquisition by Stanley Black ... Recognized as the inventor of the first Wi-Fi-based Active ... -based RFID solutions focused on improving operational efficiency, safety ...
(Date:12/13/2014)... (PRWEB) December 12, 2014 Clarassance, a ... announced its new name: Therabron Therapeutics , Inc. ... and bronchioles (a type of structure in the lungs ... company’s mission to develop novel protein therapeutics for the ... directors decided to change the name to mark the ...
Breaking Biology Technology:ADM and DNA2.0 Enter Into Protein Engineering Technology Access and Service Agreement 2Velocity Pharmaceutical Development, LLC and Tigercat Pharma, Inc. Announce Phase 2 Results for VPD-737 in Patients With Chronic Pruritus 2Velocity Pharmaceutical Development, LLC and Tigercat Pharma, Inc. Announce Phase 2 Results for VPD-737 in Patients With Chronic Pruritus 3Velocity Pharmaceutical Development, LLC and Tigercat Pharma, Inc. Announce Phase 2 Results for VPD-737 in Patients With Chronic Pruritus 4AeroScout Founder Joins GlassesOff's Board of Directors 2AeroScout Founder Joins GlassesOff's Board of Directors 3Maryland-based Biotech Company's Path Forward in Treating Respiratory Diseases Sparks Name Change 2
Cached News: